View Older Stories
-
Kura Oncology reports combination trial data for KOMZIFTI with venetoclax
-
Kura Oncology's (KURA) Zitfo Has Meaningful Edge - Citizens
-
KOMZIFTI added to NCCN guidelines for relapsed AML treatment
-
Jefferies Reiterates Buy Rating on Kura Oncology (KURA)
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) PT Raised to $25 at Leerink Partners
-
Kura Oncology receives FDA approval for blood cancer drug
-
Kura Oncology (KURA) halted, news pending
-
Kura Oncology (KURA) Misses Q3 EPS by 10c
-
Kura Oncology receives $30 million milestone from Kyowa Kirin partnership
-
Kura Oncology and Kyowa Kirin to present ziftomenib data at ASH meeting
-
Kura Oncology (KURA) Shares Could Go Higher After AML Drug Approval Says Citizens
-
Kura Oncology receives $30 million milestone from Kyowa Kirin partnership
-
Citizens Highlights Kura Oncology’s (KURA) KO-2806 Potential, Reiterates at Outperform
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Kura Oncology and Kyowa Kirin begin trial combining cancer drugs for AML
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
Kura Oncology publishes ziftomenib trial data in oncology journal
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
Kura Oncology presents preclinical data on drug combination therapy
-
Guggenheim Starts Kura Oncology (KURA) at Neutral
-
Kura Oncology (KURA) PT Lowered to $24 at Citizens JMP
-
Kura Oncology (KURA) Misses Q2 EPS by 34c
-
Cantor Fitzgerald Reiterates Overweight Rating on Kura Oncology (KURA)
-
Cantor Fitzgerald Reiterates Overweight Rating on Kura Oncology (KURA)
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
Leerink Partners Reiterates Outperform Rating on Kura Oncology (KURA)
-
Cantor Fitzgerald Reiterates Overweight Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) and Kwoya Kirin announce positive Ziftomenib data
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Cantor Fitzgerald Reiterates Overweight Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) and Kyowa Kirin announce abstract on ziftomenib trial
-
Kura Oncology (KURA) Misses Q1 EPS by 4c
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
-
Kura Oncology (KURA) Announces Preclinical Data for KO-2806
-
Kura Oncology (KURA) Tops Q4 EPS by 35c
-
BTIG Downgrades Kura Oncology (KURA) to Neutral
-
Kura Oncology (KURA) PT Raised to $40 at H.C. Wainwright
-
Kura Oncology (KURA) and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

